Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1375.

https://doi.org/10.1182/blood-2019-124963

Published: 2019

Journal Articles

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo

Sharlene Adams, Meghan Kelly, Rebecca McCarthy, Alan Wilhelm, Krystal Watkins, Leanne Lanieri, Callum M. Sloss, Angela Romanelli

Blood (2017) 130 (Supplement 1): 1357.

https://doi.org/10.1182/blood.V130.Suppl_1.1357.1357

Published: 2017

Journal Articles

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

Watkins M Krystal, MS, Russell Walker, MS, Nathan Fishkin, PhD, Charlene Audette, Yelena Kovtun, PhD, Angela Romanelli, PhD

Blood (2015) 126 (23): 1366.

https://doi.org/10.1182/blood.V126.23.1366.1366

Published: 2015

Journal Articles

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jutta Deckert, PhD, Jenny Tsui, BS, Leanne Lanieri, BS, Angela Romanelli, PhD

Blood (2015) 126 (23): 5125.

https://doi.org/10.1182/blood.V126.23.5125.5125

Published: 2015

Journal Articles

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Jutta Deckert, PhD, Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jenny Tsui, BS, Nemisha Dawra, BS, Yong Yi, MD, Jennifer A Coccia, BS, Leanne Lanieri, BS, Sharon Chicklas, BS, Angela Romanelli, PhD

Blood (2015) 126 (23): 1548.

https://doi.org/10.1182/blood.V126.23.1548.1548

Published: 2015

Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 3119.

https://doi.org/10.1182/blood.V124.21.3119.3119

Published: 2014

Journal Articles

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anastasios Stathis, MD, Arnold S. Freedman, MD, Ian W. Flinn, MD, Kami J. Maddocks, MD, Steven Weitman, MDPhD, Jesus G. Berdeja, MD, Alex V. Mejia, MD, Emanuele Zucca, MD, Rebecca Green, Angela Romanelli, PhD, Sybil H Zildjian, MPH, Rodrigo Ruiz-Soto, MD MSc, Lia Palomba, MD

Blood (2014) 124 (21): 1760.

https://doi.org/10.1182/blood.V124.21.1760.1760

Published: 2014

Journal Articles

The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies

Patrick Griffin, MD, Steffan T Nawrocki, PhD, Takashi Satou, PhD, Claudia M Espitia, MS, Kevin R. Kelly, MD, Maki Hasegawa, Swaminathan Padmanabhan, MBBS, MD, Angela Romanelli, Ron de Jong, PhD, Jennifer S Carew, PhD

Blood (2011) 118 (21): 581.

https://doi.org/10.1182/blood.V118.21.581.581

Published: 2011

Journal Articles

The Novel Aurora Kinase Inhibitor AS703569 Shows Potent Anti-Tumor Activity in Acute Myeloid Leukemia (AML).

Samantha Sarno, PhD, Jamie Shaw, B.S., Edward Spooner, B.S., Jianguo Ma, Ph.D., Ann Clark, Ph.D., Charles Dumontet, M.D., Ph.D., Angela Romanelli, Ph.D.

Blood (2007) 110 (11): 915.

https://doi.org/10.1182/blood.V110.11.915.915

Published: 2007

Journal Articles

Inhibition of Multiple Myeloma Cells Growth by AS602868, a Pharmacological Inhibitor of IKK2.

Michel Jourdan, PhD, Jerome Moreaux, PhD, Dirk Hose, MD, Jean-Francois Rossi, MD, PhD, Karène Mahtouk, PhD, Mathieu Aboulaze, Nicolas Robert, Marion Baudard, MD, PhD, Thierry Reme, MD, PhD, Angela Romanelli, Hartmut Goldschmidt, MD, Michel Dreano, PhD, Bernard Klein, MD, PhD

Blood (2006) 108 (11): 3472.

https://doi.org/10.1182/blood.V108.11.3472.3472

Published: 2006

NARROW

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies

The Novel Aurora Kinase Inhibitor AS703569 Shows Potent Anti-Tumor Activity in Acute Myeloid Leukemia (AML).

Inhibition of Multiple Myeloma Cells Growth by AS602868, a Pharmacological Inhibitor of IKK2.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only